

Literaturverzeichnis

Abdel Gadir A, Mowafi R, Alnaser H et al.: Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulation hormone therapy in the treatment of patients with PCO-disease. Clin Endocrinol 1990; 33: 585-592

Abdel Gadir A, Alnaser H, Mowafi R et al.: The response of patients with polycystic ovarian disease to human menopausal gonadotrophin therapy after ovarian electrocautery or a luteinizing hormone- releasing agonist. Fert Steril 1992; 57: 309-313

Abdel Gadir A, Khatim MS, Alnaser H et al.: Ovarian electrocautery: Responders versus non-responders. Gynecol Endocrinol 1993; 7: 43-48

Achard C, Thiers J: Le virilisme pileux et son association a l'insuffisance glycotique (diabetes des femmes a barbe). Bull Acad Nat Med 1921; 86: 51-64

Amato P, Simpson JL: The genetics of polycystic ovary syndrome. Best Practice and Research Clinical Obstetrics and Gynecology 2004; 18 (5): 707-718

Archer JS, Chang RJ: Hirsutism and acne in polycystic ovary syndrome. Best Practice and Research Clinical Obstetrics and Gynecology 2004; 18(5): 737-754

Armar N, McGarrigle H, Honour J et al.: Laparoscopic ovarian surgery in the management of anovulatory infertility in women with PCOS: Endocrine changes and clinical outcomes. Fert Steril 1990; 53: 45-49

Azziz R: The evaluation and management of hirsutism. Obstet Gynecol 2003; 101: 995-1007

Balen AH, Tan SL, Jacobs HS: Hypersecretion of luteinising hormone – a significant cause of subfertility and miscarriage. Br J Obstet Gynecol 1993; 100: 1082-1089

Balen AH: The pathogenesis of polycystic ovary syndrome: The enigma unravels. *Lancet* 1999; 354: 966-967

Balen AH: The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. *Best Practice and Research Clinical Obstetrics and Gynecology* 2004; 18 (5): 685-706

Barbieri RL, Ryan KJ: Hyperandrogenism, insulin resistance and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. *Am J Obstet Gynecol* 1983; 147: 90-101

Baron J: Diagnostik und Therapie des Hirsutismus. *Zentralbl Gynäkol* 1974; 5: 129-142

Bayram N, van Wely M, van der Veen F: Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with PCOS. *Cochrane Database of Systematic Reviews* 2001, Issue 2: CD002121

Bayram N, van Wely M, Kaaijk EM et al.: Using an electrocautery strategy and recombinant follicle stimulating hormone: Randomised controlled trial. *Br Med J* 2004; 328: 192-196

Beck JL, Boothroyd C, Proctor M et al.: Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. *Cochrane Database of Systematic Reviews* 2005; 1: CD002249

Ben-Haroush A, Yogev Y, Fisch B: Insulinresistance and metformin in polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol* 2004; 115: 125-133

Bühling KJ, Bartley J, Lübbert H: Einsatz oraler Antidiabetika in der Therapie des Kinderwunsches, des Gestationsdiabetes und zur Prävention des Typ 2 Diabetes. *Geb Fra* 2006; 66: 1-5

Cattrall FR, Healy DL: Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. *Best Practice and Research Clinical Obstetrics and Gynecology* 2004; 18 (5): 803-812

Christin-Maitre S, Hugues JN: A comparative randomized multicentric study comparing step-up versus step-down-protocol in PCOS. *Hum Reprod* 2003; 18: 1626-1631

Ciampelli M, Fulghesu AM, Cucinelli F et al.: Heterogeneity in cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with PCOS. *Hum Reprod* 1997, 12: 1897-1901

Ciampelli M, Fulghesu AM, Cucinelli F et al.: Impact of insulin and body mass index on metabolic and endocrine variables in PCOS. *Metabolism* 1999; 48: 167-172

Clark AM, Ledger W, Galletly C et al.: Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Hum Reprod* 1995; 10: 2705-2712

Cohen BM: Laser laparoscopy for polycystic ovaries. *Fert Steril* 1989; 52: 167-168

Connaughton JF, Garcia C-R, Wallach EE: Induction of ovulation with clomiphene and a placebo. *Obstet Gynecol* 1974; 43 (5): 697-701

Conway GS, Agrawal R, Betteridge DJ et al.: Risk factors for coronary artery disease in lean and obese women with the PCOS. *Clin Endocrinol* 1992; 37: 119-125

Crosignani PG, Colombo M, Vegetti W et al.: Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. *Hum Reprod* 2003; 9: 1928-1923

Dahlgren E, Landin K, Krotkiewski M et al.: Effects of two antiandrogen treatments on hirsutism in women with polycystic ovary syndrome. *Hum Reprod* 1998; 10: 2706-2711

De Leo V, la Marca A, Ditto A et al.: Effects of metformin on gonadotropin-induced ovulation women with PCOS. *Fert Steril* 1999; 72: 282-285

Dereli D, Ozgen G, Buyukkececi F et al.: Platelet dysfunction in lean women with PCOS and association with insulin sensitivity. *J Clin Endocrinol Metabol* 2003; 88: 2263-2268

Diamanti-Kandarakis E, Kolui C, Tsianateli T et al.: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in in polycystic ovary syndome. *Eur J Endocrinol* 1998; 138: 269-274

Diamanti-Kandarakis E, Kolui C, Alexandraki K et al.: Failure of mathematical indices to accurately assess insulin resistance in lean, overweight or obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004; 89: 1273-1276

Dunaif A, Segal KR, Futterweil W et al.: Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. *Diabetes* 1989; 38: 1165-1174

Elnashar A, Abdelmageed E, Fayed M et al.: Clomiphene citrate and dexamethazone in treatment of clomiphene citrate resistant polycystic ovary syndrome: A prospective placebo-controlled study, *Hum Reprod* 2006; 21: 1805-1808

Elsenbruch S, Hahn S, Kowalsky D et al.: Quality of life, psychological well-being and sexual satisfaction in women with polycystic ovary syndrome. *J Clin Endocrinol Metabol* 2003; 88: 5801-5807

Elter K, Imir G, Durmusoglu F: Clinical, endocrine and metabolic effects of metformin added to ethinylestradiol- cyproterone acetate in non-obese women with with polycystic ovarian syndrome: A randomised controlled study. *Hum Reprod* 2002; 17: 1729-1737

Elting MW, Korsen TJM, Bezemer PD et al.: Prevalence of diabetes mellitus, hypertension and cardiac complains in a follow-up study of a Dutch PCOS-population. *Hum Reprod* 2001; 16: 556-560

Erdem NT, Ercan ME, Akyolcu MC et al.: Plasma viscosity as an early cardiovascular risk factor in hirsute women with eumenorrhea or oligomenorrhea. *Fert Steril* 2003; 80: 1195-1198

Fahri J, Soule S, Jacobs HS: Effect of laparoscopic ovarian electrocautery on ovarian response and outcome treatment with gonadotrophins in clomiphene resistant patients with PCOS. *Fert Steril* 1995; 64: 930-935

Farquhar CM, Williamson K, Gudex G et al.: A randomised controlled trial of laparoscopic ovarian versus gonadotrophin therapy for women with clomiphene resistant PCOS. *Fert Steril* 2002; 78 (2): 404-411

Farquhar CM, Lee O, Toomath R et al.: Spironolactone versus placebo or in combination with steroids for hirsutism and / or acne. *Cochrane Database of Systematic Reviews* 2003, 4: CD000194

Farquhar CM: The role of ovarian surgery in polycystic ovary syndrome. *Best Practice and Research Clinical Obstetrics and Gynecology* 2004; 18 (5): 789-802

Farquhar CM, Lilford RJ, Marjoribanks J et al.: Laparoscopic „drilling“ by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. *Cochrane Database of Systematic Reviews* 2005; 3: CD001122

Fauser B, Tarlatzis B, Chang J et al.: The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004; 19: 41-47

Felberbaum R, Ortmann O et al.: Ovarielle Stimulation: Möglichkeiten und Komplikationen. In *Weibliche Sterilität – Ursachen, Diagnostik und Therapie*. Hrsg. K. Diedrich, Springer-Verlag 1998

Fenkci V, Fenkci S, Yilmazer M et al.: Decreased total antioxidant status and increased oxidative stress in women with PCOS may contribute to the risk of cardiovascular disease. *Fert Steril* 2003; 80 : 123-127

Franks S: Polycystic ovary syndrome. *N Engl J Med* 1995; 333: 853-861

Fraser IS, Kovacs G: Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. *Best Practice and Research Clinical Obstetrics and Gynecology* 2004; 18 (5): 813-823

Ghazeeri G, Kutteh WH, Bryer-Ash M et al.: Effect of rosiglitazone on spontaneous and clomiphene citrate - induced ovulation in women with PCOS. *Fert Steril* 2003; 79: 562-566

Glueck CJ, Wang P, Fontaine R et al.: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrhoeic women with the polycystic ovary syndrome. *Metabolism* 1999; 48: 511-519

Glueck CJ, Wang P, Kobayashi S et al.: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with PCOS. *Fert Steril* 2002; 77: 520-525

Glueck CJ, Wang P, Goldenberg N et al.: Pregnancy outcomes among women with PCOS treated with Metformin. *Hum Reprod* 2002; 17: 2858-2864

Glueck CJ, Papanna R, Wang P et al.: Incidence and treatment of metabolic syndrome in newly referred women with confirmed PCOS. *Metabolism* 2003; 52: 908-915

Gjonnaess H: Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. *Fert Steril* 1984; 49: 956-960

Gjonnaess H: Ovarian electrocautery in the treatment of women with PCOS. *Acta Obstet Gynecol Scand* 1994; 73: 407-412

Gjonnaess H: Late endocrine effects of ovarian electrocautery in women with PCOS. Fert Steril 1998; 69: 697-701

Goldzieher JW, Green JA: The polycystic ovary : Clinical and histological features. J Clin Endocrinol Metabol 1962; 22: 325-338

Graf MA, Weiers C, Graf C et al.: Dexamethason normalisiert nicht die gestörte LH-Pulsatilität bei der hyperandrogenämischen Ovarialinsuffizienz. Geb Fra 1992; 52: 35-41

Graf MA: PCO-Syndrom und Hyperandrogenämie. CME Praktische Fortbildung – Gynäkologie, Geburtsmedizin und Gynäkologische Endokrinologie 3/2006, akademos Wissenschaftsverlag

Greenblatt E, Caspar RF: Endocrine changes after laparoscopic ovarian cautery in PCOS. Am J Obstet Gynecol 1987, 156: 279-285

Greenblatt E, Caspar RF: Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fert Steril 1993; 60: 766-770

Guzick DS, Talbott E, Sutton-Tyrrell K et al.: Carotid arteriosclerosis in women with PCOS: Initial results from a case-control study. Am J Obstet Gynecol 1996; 174: 1224-1229

Gysler M, March CM, Mishell DR et al.: A decade's experience with an individualized clomiphene treatment regimen including its effects on the postcoital test. Fert Steril 1982; 37: 161-167

Hahn S, Quadbeck B, Elsenbruch S et al.: Metformin – Ein effektiver Therapieansatz in der Behandlung des Polyzystischen Ovarsyndroms. Dtsch Med Wochenschr 2004; 129: 1059-1064

Harborne L, Fleming R, Lyall H et al.: Metformin or antiandrogen in the treatment of hirsutism in PCOS. *J Clin End Metabol* 2003; 88: 4116-4123

Hart R, Hickey M, Franks S: Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. *Best Practice and Research Clinical Obstetrics and Gynecology* 2004; 18 (5): 671-683

Homburg R: Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. *Best Practice and Research Clinical Obstetrics and Gynecology* 2004; 18 (5): 773-788

Imani B, Eijkemans MJ, te Velde ER: Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrhoeic infertility. *J Clin Endocrinol Metabol* 1998; 83: 2361-2365

Jakubowicz DJ, Luorno MJ, Jakubowicz S et al.: Effects of Metformin on early pregnancy loss in the PCOS. *J Clin Endocrinol Metabol* 2002; 87: 524-529

Johnson JE, Cohen MR, Goldfarb AF et al.: The efficacy of clomipene citrate for induction of ovulation. *Int J Fert* 1966; 11: 265-270

Katz M, Carr PJ, Cohen BM et al.: Hormonal effects of wedge resection of polycystic ovaries. *Obstet Gynecol* 1978; 23: 93-99

Kelly CJG, Gordon D: The effect of metformin on hirsutism in polycystic ovary syndrome. *Eur J Endocrinol* 2002; 147: 217-221

Keck C, Neulen J, Breckwoldt N: Ovarian hyperstimulation syndrome. *Geb Fra* 1994; 54: 315-320

Kiddy DS, Hamilton-Fairley D, Bush A et al.: Improvement of endocrine and ovarian function during dietary treatment of obese women with PCOS. *Clin Endocrinol* 1992; 36: 1105-1111

Kirchengast S, Huber J: Body composition characteristics and body fat distribution in lean women with PCOS. *Hum Reprod* 2001; 16: 1255-1260

Kjotrod SB, Düring von V, Carlsen SM: Metformin treatment before IVF/ ICSI in women with polycystic ovary syndrome; a prospective, randomized, double-blind study. *Hum Reprod* 2004; 19(6): 1315-1322

Lakhani K, Seifalian AM, Atiomo WU et al.: Polycystic ovaries. *Br J Radiol* 2002; 75: 9-16

Lam PM, Cheung LP, Haines C: Revisit of metformin treatment in polycystic ovarian syndrome. *Gynecol Endocrinol* 2004; 19: 33-39

Laven JS, Imani B, Eijkemans MJ et al.: New approaches to PCOS and other forms of anovulation. *Obstet Gynecol Surv* 2002; 57 : 755-767

Lazovic G, Milacic D, Terzic M et al.: Medicaments or surgical therapy of PCOS. *Fert Steril* 1998; 70 (3): 472 (abstract)

Legro RS, Kunselmann AR, Dodson WC et al.: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective controlled study in 204 affected women. *J Clin Endocrinol Metabol* 1999; 84: 165-169

Legro RS: Diagnostic criteria in polycystic ovary syndrome. *Sem Reprod Med* 2003; 21 (3): 267-275

Li TC, Saravelos H, Chow MS et al.: Factors affecting the outcome of laparoscopic ovarian drilling for PCOS in women with anovulatory infertility. *Br J Obstet Gynecol* 1998; 105: 338-344

Lord JM, Flight IH, Norman RJ: Insulin sensitizing drugs (Metformin, trogliazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. *Cochrane Database of Systematic Reviews* 2003; 3: CD003053

Ludwig E: Classification of the types of androgenic alopecia (common baldness) occurring in the female sex. *Br J Dermatol* 1977; 97(3): 247-254

McCarthy EA, Walker SP, McLachlan K et al.: Metformin in obstetric and gynecologic practice: A Review. *Obstet Gynecol Surv* 2004; 59: 118-127

Mitwally MF, Casper RF. Use of aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. *Fertil Steril* 2001; 75: 305-309

Moran L, Norman RJ: Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. *Best Practice and Research Clinical Obstetrics and Gynecology* 2004; 18 (5): 719-736

Muth S, Norman J, Sattar N et al.: Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined: indications for a change in licensing arrangements? *Hum Reprod* 2004, 12, 2718-2720

Nestler JE, Jakubowicz DJ, Evans WS et al.: Effects of metformin on spontaneous and clomiphene induced ovulation in the polycystic ovary syndrome. *N Engl J Med* 1998; 338: 1876-1880

Nestler JE, Stovall D, Akhter N et al.: Strategies for the use of insulin sensitizing drugs to treat infertility in women with PCOS. *Fert Steril* 2002; 77: 209-215

Ortmann O: Diagnostik und Therapie des polyzystischen Ovarsyndroms. In „Weibliche Sterilität“; Hrsg. K. Diedrich, Springer-Verlag 1998

Palomba S, Orio F, Fabro A et al.: Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as first line treatment for ovulation induction in nonobese anovulatory women with polycystic oavray syndrome. *J Clin Endocrinol Metab* 2005; 90: 4068-4074

Pasquali R, Antenucci D, Casmirri F et al.: Clinical and hormonal characteristics of obese amenorrhoeic hyperandrogenic women before and after weight loss. *J Clin Endocrinol Metabol* 1989; 68: 173-179

Raudrant D, Rabe T: Progesterons with antiandrogenic properties. *Drugs* 2003; 63: 463-492

Rodin DA, Bano G, Bland JM et al.: Polycystic ovaries and associated metabolic abnormalities in indian subcontinent Asian women. *Clin Endocrinol* 1998; 49(1): 91-99

Rosenfield RL, Barnes RB, Cara JF et al.: Dysregulation of cytochrom P450 c17 α as the cause of PCOS. *Fert Steril* 1990; 53 (5): 785-791

Saleh AM, Khalil HS: Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome. *Acta Obstet Gynecol Scand* 2004; 83: 614-621

Schüring AN, Kiesel L: Hormonelle Therapie des polycystischen Ovarsyndroms (PLOS). *Gynäkologe* 2005; 38: 333-341

Schildkraut JM, Schwingl PJ, Bastos E et al.: Epithelial ovarian cancer risk among women with polycystic ovarian syndrome. *Obstet Gynecol* 1996, 88: 554-559

Silfen ME, Denburg MR, Manibo AM et al.: Early endocrine, metabolic and sonographic characteristics of PCOS syndrome: Comparison between nonobese and obese adolescents. *J Clin Endocrinol Metabol* 2003; 88: 4682-4688

Sowers JR: Obesity as a cardiovascular risk factor. *Am J Med* 2003; 115 (Suppl 1): 37-41

Stadtmauer LA, Toma SK, Riehl RM et al.: Metformin treatment of patients with PCOS undergoing in vitro fertilisation improves outcomes and is associated with modulation of the insulin-like growth factors. *Fert Steril* 2001; 75: 505-509

Stein IF, Leventhal NL: Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935; 29: 181-191

Stein IF, Cohen MR: Surgical treatment of bilateral polycystic ovaries. *Am J Obstet Gynecol* 1939; 38: 465-473

Strowitzki T, Seehaus D, Korell M et al.: Low dose follicle stimulating hormone for ovulation induction in PCOS. *J Reprod Med* 1994; 39: 499-503

Strowitzki T, Halser B, Demant T: Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with PCOS. *Gynecol Endocrinol* 2002; 16: 45-51

Talbott E, Guzick D, Clericy A et al.: Coronary heart disease risk factors in women with PCOS. *Arteriosclerosis, Thrombosis and Vascular Biology* 1995; 15 : 821-826

Tan SL, Fahri J, Homburg R et al.: Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH. *Obstet Gynecol* 1996 88: 221-226

Taponen S, Ahonkallio S, Martikainen H et al.: Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/ or hirsutism: Northern Finland Birth Cohort 1966 Study. *Hum Reprod* 2004; 19(5): 1083- 1088

Tartagni M, Schonauer LM, De Salvia MA et al.: Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. *Fert Steril* 2000; 73: 718-723

Taylor AE, McCourt B, Martin K et al.: Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. *J Clin Endocrinol Metabol* 1997; 82: 2248-2256

Tucci S, Futterweit W, Conception ES et al.: Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor gene locus. *J Clin Endocrinol Metabol* 2001; 86: 446-449

Van Der Meer M, Hompes PGA, de Boer J et al.: Cohort size rather than follicle-stimulating hormone threshold levels determines ovarian sensitivity in PCOS. *J Clin Endocrinol Metabol* 1998; 83: 423-426

Vandermolen DT, Retts VS, Evans WS et al.: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with PCOS who are resistant to clomiphene citrate alone. *Fertil Steril* 2001; 75: 310-315

Vegetti W, Ragni G, Baroni E et al.: Laparoscopic ovarian versus low-dose pure FSH in anovulatory clomiphene-resistant patients with PCOS: Randomized prospective study. *Hum Reprod* 1998; 13 (1): 120 (abstract)

Velazquez EM, Mendoza S, Hamer T et al.: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. *Metabolism* 1994; 43: 647-654

Venn A, Watson L, Bruinsma F et al.: Risk of cancer after use of fertility drugs with in-vitro fertilisation. *Lancet* 1999; 354: 1586-1590

Verhelst J, Gerris J, Joostens M et al.: Clinical and endocrine effects of laser vaporization in patients with polycystic ovarian disease. *Gynecol Endocrinol* 1993; 7: 49-55

Vrbikova J, Bendlova B, Martin H et al.: Insulin sensitivity and β -cell function in women with PCOS. *Diabetes Care* 2002; 25: 1217-1222

Waldstreicher J, Santoro NF, Hall HJE et al.: Hyperfunction of the hypothalamic-pituitary-axis in women with polycystic ovarian disease: Indirect evidence of partial gonadotroph desensitization. *J Clin Endocrinol Metabol* 1988; 66: 165-172

Wijeyaratne CN, Balen AH, Barth J et al.: Clinical manifestations and insulin resistance in polycystic ovary syndrome among south asian and caucasians: Is there a difference? *Clin Endocrinol* 2002; 57 : 343- 350

Ying T, Liangzhi X, Taixiang W et al.: Laparoscopic ovarian diathermy versus metformin for women with polycystic ovarian syndrome (Protocol). Cochrane Database of Systematic Reviews 2006; 4: CD006223